Citations (50)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (17)
Eliel Nham, Hye Seong, Hakjun Hyun, Jin Gu Yoon, Ji Yun Noh, Hee Jin Cheong, Woo Joo Kim, Eugene Kim, Leejung Choi, Jung-Min Lee & Joon Young Song. (2023) Cost-effectiveness of high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccine for older people in a country with high influenza vaccination rate. Human Vaccines & Immunotherapeutics 19:3.
Read now
Read now
Antonio Arbo, Celia Martinez-Cuellar, Cynthia Vazquez, Lucile Bellier, Cecilia Adorno, Hugo Dibarboure, Juan Guillermo Lopez, Audrey Petitjean & Pablo Bianculli. (2022) Public health and budget impacts of switching from a trivalent to a quadrivalent inactivated influenza vaccine in Paraguay. Human Vaccines & Immunotherapeutics 18:5.
Read now
Read now
Pablo Manuel Bianculli, Lucile Bellier, Ignacio Olivera Mangado, Carlos Grau Pérez, Gustavo Mieres, Luis Lazarov, Audrey Petitjean, Hugo Dibarboure & Juan Guillermo Lopez. (2022) Switching from trivalent to quadrivalent inactivated influenza vaccines in Uruguay: a cost-effectiveness analysis. Human Vaccines & Immunotherapeutics 18:5.
Read now
Read now
Guillermo M. Ruiz-Palacios, John H. Beigel, Maria Lourdes Guerrero, Lucile Bellier, Ramiro Tamayo, Patricia Cervantes, Fabián P. Alvarez, Arturo Galindo-Fraga, Felipe Aguilar-Ituarte & Juan Guillermo Lopez. (2020) Public health and economic impact of switching from a trivalent to a quadrivalent inactivated influenza vaccine in Mexico. Human Vaccines & Immunotherapeutics 16:4, pages 827-835.
Read now
Read now
Viviane Gresset-Bourgeois, Phillip S. Leventhal, Stéphanie Pepin, Rosalind Hollingsworth, Marie-Pierre Kazek-Duret, Iris De Bruijn & Sandrine I. Samson. (2018) Quadrivalent inactivated influenza vaccine (VaxigripTetra™). Expert Review of Vaccines 17:1, pages 1-11.
Read now
Read now
Riju Ray, Gaël Dos Santos, Philip O. Buck, Carine Claeys, Gonçalo Matias, Bruce L. Innis & Rafik Bekkat-Berkani. (2017) A review of the value of quadrivalent influenza vaccines and their potential contribution to influenza control. Human Vaccines & Immunotherapeutics 13:7, pages 1640-1652.
Read now
Read now
Pieter T. de Boer, Britt M. van Maanen, Oliver Damm, Bernhard Ultsch, Franklin C.K. Dolk, Pascal Crépey, Richard Pitman, Jan C. Wilschut & Maarten J. Postma. (2017) A systematic review of the health economic consequences of quadrivalent influenza vaccination. Expert Review of Pharmacoeconomics & Outcomes Research 17:3, pages 249-265.
Read now
Read now
Aurélien Jamotte, Emilie Clay, Bérengère Macabeo, Andrès Caicedo, Juan Guillermo Lopez, Lucia Bricks, Martín Romero Prada, Rubén Marrugo, Pamela Alfonso, Brechla Moreno Arévalo, Danilo Franco, Lourdes Garcia Diaz & Yadira Isaza de Molto. (2017) Public health impact and economic benefits of quadrivalent influenza vaccine in Latin America. Human Vaccines & Immunotherapeutics 13:4, pages 877-888.
Read now
Read now
Anita J. Brogan, Sandra E. Talbird, Ashley E. Davis, Edward W. Thommes & Genevieve Meier. (2017) Cost-effectiveness of seasonal quadrivalent versus trivalent influenza vaccination in the United States: A dynamic transmission modeling approach. Human Vaccines & Immunotherapeutics 13:3, pages 533-542.
Read now
Read now
Ming-Chin Yang, Elise Chia-Hui Tan & Jian-Jhih Su. (2017) Cost-effectiveness analysis of quadrivalent versus trivalent influenza vaccine in Taiwan: A lifetime multi-cohort model. Human Vaccines & Immunotherapeutics 13:1, pages 81-89.
Read now
Read now
B. M. Van Maanen, P. T. de Boer, F. C. K. Dolk, A. W. Friedrich, J. C. Wilschut, R. Pitman & M. J. Postma. (2017) Dynamic modelling approaches for the analysis of the cost-effectiveness of seasonal influenza control. Expert Review of Vaccines 16:1, pages 1-4.
Read now
Read now
Corwin A. Robertson, Peter Tsang, Victoria A. Landolfi & David P. Greenberg. (2016) Fluzone® Intradermal Quadrivalent Influenza Vaccine. Expert Review of Vaccines 15:10, pages 1245-1253.
Read now
Read now
Mathieu Uhart, Hélène Bricout, Emilie Clay & Nathalie Largeron. (2016) Public health and economic impact of seasonal influenza vaccination with quadrivalent influenza vaccines compared to trivalent influenza vaccines in Europe. Human Vaccines & Immunotherapeutics 12:9, pages 2259-2268.
Read now
Read now
Yueyuan Zhao, Xuefeng Zhang, Fengcai Zhu, Hui Jin & Bei Wang. (2016) A preliminary cost-effectiveness analysis of hepatitis E vaccination among pregnant women in epidemic regions. Human Vaccines & Immunotherapeutics 12:8, pages 2003-2009.
Read now
Read now
G. Meier, M. Gregg & B. Poulsen Nautrup. (2015) Cost-effectiveness analysis of quadrivalent influenza vaccination in at-risk adults and the elderly: an updated analysis in the UK. Journal of Medical Economics 18:9, pages 746-761.
Read now
Read now
Hans de Graaf & Saul N Faust. (2015) Fluarix quadrivalent vaccine for influenza. Expert Review of Vaccines 14:8, pages 1055-1063.
Read now
Read now
Richard Aspinall & Pierre Olivier Lang. (2014) Vaccine responsiveness in the elderly: best practice for the clinic. Expert Review of Vaccines 13:7, pages 885-894.
Read now
Read now
Articles from other publishers (33)
Syed Mohamed Aljunid, Nur Syazana Mad Tahir, Aniza Ismail, Aznida Firzah Abdul Aziz, Amirah Azzeri, S. A. Zafirah & Azimatun Noor Aizuddin. (2023) Cost effectiveness of quadrivalent influenza vaccines in the elderly population of Malaysia. Scientific Reports 13:1.
Crossref
Crossref
Maarten Postma, David Fisman, Norberto Giglio, Sergio Márquez-Peláez, Van Hung Nguyen, Andrea Pugliese, Jesús Ruiz-Aragón, Analia Urueña & Joaquin Mould-Quevedo. (2023) Real-World Evidence in Cost-Effectiveness Analysis of Enhanced Influenza Vaccines in Adults ≥ 65 Years of Age: Literature Review and Expert Opinion. Vaccines 11:6, pages 1089.
Crossref
Crossref
Clara R. Warmath, Ismael R. Ortega-Sanchez, Lindsey M. Duca, Rachael M. Porter, Molly G. Usher, Joseph S. Bresee, Kathryn E. Lafond & William W. Davis. (2023) Comparisons in the Health and Economic Assessments of Using Quadrivalent Versus Trivalent Influenza Vaccines: A Systematic Literature Review. Value in Health 26:5, pages 768-779.
Crossref
Crossref
Desmond Loong, Ba’ Pham, Mohammadreza Amiri, Hailey Saunders, Sujata Mishra, Amruta Radhakrishnan, Myanca Rodrigues, Man Wah Yeung, Matthew P. Muller, Sharon E. Straus, Andrea C. Tricco & Wanrudee Isaranuwatchai. (2022) Systematic Review on the Cost-Effectiveness of Seasonal Influenza Vaccines in Older Adults. Value in Health 25:8, pages 1439-1458.
Crossref
Crossref
Amine Amiche, Mine Durusu Tanriover, Lucile Bellier, Baris Ugur & Levent Akin. (2021) Cost Utility of Switching From Trivalent to Quadrivalent Influenza Vaccine in Turkey. Value in Health Regional Issues 25, pages 15-22.
Crossref
Crossref
Lucile Bellier, Audrey Petitjean, Tatiana Sarazu, Julio Tresierra & Juan Guillermo Lopez. (2021) Cost-effectiveness analysis of switching from a trivalent to a quadrivalent inactivated influenza vaccine in the Peruvian immunisation programme. Vaccine 39:30, pages 4144-4152.
Crossref
Crossref
Pierre Net, Florian Colrat, Mafalda Nascimento Costa, Florence Bianic, Edward Thommes & Fabián P. Alvarez. (2021) Estimating public health and economic benefits along 10 years of Fluzone® High Dose in the United States. Vaccine 39, pages A56-A69.
Crossref
Crossref
Florian Zeevat, Pascal Crépey, F. Christiaan K. Dolk, Arjan J. Postma, Vidya N.A. Breeveld-Dwarkasing & Maarten J. Postma. (2021) Cost-Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in the Dutch National Influenza Prevention Program. Value in Health 24:1, pages 3-10.
Crossref
Crossref
Helena C. MaltezouAthanassios KossyvakisTheodore LytrasMaria ExindariMaria ChristoforidiAndreas MentisGeorgia Gioula. (2020) Circulation of Influenza Type B Lineages in Greece During 2005–2015 and Estimation of Their Impact. Viral Immunology 33:2, pages 94-98.
Crossref
Crossref
Kimberly J. Wilson, H. Shelton Brown, Ujas Patel, Debbie Tucker & Kurt Becker. (2020) Cost-effectiveness of a comprehensive immunization program serving high-risk, uninsured adults. Preventive Medicine 130, pages 105860.
Crossref
Crossref
D. Shasha, L. Valinsky, F. Hershkowitz Sikron, A. Glatman-Freedman, M. Mandelboim, A. Toledano, Y. Paran, R. Ben-Ami & D. Goldman. (2020) Quadrivalent versus trivalent influenza vaccine: clinical outcomes in two influenza seasons, historical cohort study. Clinical Microbiology and Infection 26:1, pages 101-106.
Crossref
Crossref
Gideon O Emukule, Fredrick Otiato, Bryan O Nyawanda, Nancy A Otieno, Caroline A Ochieng, Linus K Ndegwa, Peter Muturi, Godfrey Bigogo, Jennifer R Verani, Philip M Muthoka, Elizabeth Hunsperger & Sandra S Chaves. (2019) The Epidemiology and Burden of Influenza B/Victoria and B/Yamagata Lineages in Kenya, 2012–2016. Open Forum Infectious Diseases 6:10.
Crossref
Crossref
Yun-Kyung Kim, Joon Young Song, Hyeongap Jang, Tae Hyun Kim, Heejo Koo, Lijoy Varghese & Euna Han. (2018) Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea. PharmacoEconomics 36:12, pages 1475-1490.
Crossref
Crossref
José Antonio López Trigo, Rosa López Mongil, Alberto Mariano Lázaro, Gloria Mato Chaín, Norberto Moreno Villajos & Primitivo Ramos Cordero. (2018) Vacunación frente a la gripe estacional en las personas mayores. Evaluación de la vacuna tetravalente. Informe de posicionamiento. Revista Española de Geriatría y Gerontología 53, pages 185-202.
Crossref
Crossref
Kuen-Cheh Yang, Hui-Fang Hung, Meng-Kan Chen, Sam Li-Sheng Chen, Jean Ching-Yuan Fann, Sherry Yueh-Hsia Chiu, Amy Ming-Fang Yen, Kuo-Chin Huang, Hsiu-Hsi Chen & Sen-Te Wang. (2018) Cost-effectiveness analysis of universal influenza vaccination: Application of the susceptible–infectious–complication–recovery model. International Journal of Infectious Diseases 73, pages 102-108.
Crossref
Crossref
Elizabeth Q. Littauer, Lisa K. Mills, Nicole Brock, E. Stein Esser, Andrey Romanyuk, Joanna A. Pulit-Penaloza, Elena V. Vassilieva, Jacob T. Beaver, Olivia Antao, Florian Krammer, Richard W. Compans, Mark R. Prausnitz & Ioanna Skountzou. (2018) Stable incorporation of GM-CSF into dissolvable microneedle patch improves skin vaccination against influenza. Journal of Controlled Release 276, pages 1-16.
Crossref
Crossref
Shinya Tsuzuki, Markus Schwehm & Martin Eichner. (2018) Simulation studies to assess the long-term effects of Japan’s change from trivalent to quadrivalent influenza vaccination. Vaccine 36:5, pages 624-630.
Crossref
Crossref
Rutger G. Woolthuis, Jacco Wallinga & Michiel van Boven. (2017) Variation in loss of immunity shapes influenza epidemics and the impact of vaccination. BMC Infectious Diseases 17:1.
Crossref
Crossref
Aurélien Jamotte, Chui Fung Chong, Andrew Manton, Bérengère Macabeo & Mondher Toumi. (2016) Impact of quadrivalent influenza vaccine on public health and influenza-related costs in Australia. BMC Public Health 16:1.
Crossref
Crossref
Pieter T. de Boer, Pascal Crépey, Richard J. Pitman, Bérengère Macabeo, Ayman Chit & Maarten J. Postma. (2016) Cost-Effectiveness of Quadrivalent versus Trivalent Influenza Vaccine in the United States. Value in Health 19:8, pages 964-975.
Crossref
Crossref
Christiaan Dolk, Martin Eichner, Robert Welte, Anastassia Anastassopoulou, Laure-Anne Van Bellinghen, Barbara Poulsen Nautrup, Ilse Van Vlaenderen, Ruprecht Schmidt-Ott, Markus Schwehm & Maarten Postma. (2016) Cost-Utility of Quadrivalent Versus Trivalent Influenza Vaccine in Germany, Using an Individual-Based Dynamic Transmission Model. PharmacoEconomics 34:12, pages 1299-1308.
Crossref
Crossref
Eunha Shim, Shawn T. Brown, Jay DePasse, Mary Patricia Nowalk, Jonathan M. Raviotta, Kenneth J. Smith & Richard K. Zimmerman. (2016) Cost Effectiveness of Influenza Vaccine for U.S. Children. American Journal of Preventive Medicine 51:3, pages 309-317.
Crossref
Crossref
Lisa Nagy, Terho Heikkinen, Alfred Sackeyfio & Richard Pitman. (2016) The Clinical Impact and Cost Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in Finland. PharmacoEconomics 34:9, pages 939-951.
Crossref
Crossref
Pieter T. de Boer, Geert W. J. Frederix, Talitha L. Feenstra & Pepijn Vemer. (2016) Unremarked or Unperformed? Systematic Review on Reporting of Validation Efforts of Health Economic Decision Models in Seasonal Influenza and Early Breast Cancer. PharmacoEconomics 34:9, pages 833-845.
Crossref
Crossref
Aye M. Moa, Abrar A. Chughtai, David J. Muscatello, Robin M. Turner & C. Raina MacIntyre. (2016) Immunogenicity and safety of inactivated quadrivalent influenza vaccine in adults: A systematic review and meta-analysis of randomised controlled trials. Vaccine 34:35, pages 4092-4102.
Crossref
Crossref
Long Wang, Vijayalakshmi Chandrasekaran, Joseph B. Domachowske, Ping Li, Bruce L. Innis & Varsha K. Jain. (2016) Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine in US Children 6–35 Months of Age During 2013–2014: Results From A Phase II Randomized Trial. Journal of the Pediatric Infectious Diseases Society 5:2, pages 170-179.
Crossref
Crossref
Wanitchaya Kittikraisak, Malinee Chittaganpitch, Christopher J. Gregory, Yongjua Laosiritaworn, Thanawadee Thantithaveewat, Fatimah S. Dawood & Kim A. Lindblade. (2016)
Assessment of potential public health impact of a quadrivalent inactivated influenza vaccine in
T
hailand
. Influenza and Other Respiratory Viruses 10:3, pages 211-219.
Crossref
Crossref
Ana Mosterín Höpping, Judith M. Fonville, Colin A. Russell, Sarah James & Derek J. Smith. (2016) Influenza B vaccine lineage selection—An optimized trivalent vaccine. Vaccine 34:13, pages 1617-1622.
Crossref
Crossref
Edward W. Thommes, Afisi Ismaila, Ayman Chit, Genevieve Meier & Christopher T. Bauch. (2015) Cost-effectiveness evaluation of quadrivalent influenza vaccines for seasonal influenza prevention: a dynamic modeling study of Canada and the United Kingdom. BMC Infectious Diseases 15:1.
Crossref
Crossref
Anne Mosnier, Saverio Caini, Isabelle Daviaud, Jean-Louis Bensoussan, Françoise Stoll-Keller, Tan Tai Bui, Bruno Lina, Sylvie Van der Werf & Jean Marie Cohen. (2015) Ten influenza seasons in France: distribution and timing of influenza A and B circulation, 2003–2013. BMC Infectious Diseases 15:1.
Crossref
Crossref
Yukari Tsurudome, Kazuhiko Kimachi, Yusuke Okada, Kenta Matsuura, Yusuke Ooyama, Kayo Ibaragi, Yoichiro Kino & Kohji Ueda. (2015) Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan. Microbiology and Immunology 59:10, pages 597-604.
Crossref
Crossref
Pascal Crépey, Pieter T. Boer, Maarten J. Postma & Richard Pitman. (2015) Retrospective public health impact of a quadrivalent influenza vaccine in the United States. Influenza and Other Respiratory Viruses 9:S1, pages 39-46.
Crossref
Crossref
Ayman Chit, Julie Roiz & Samuel Aballea. (2015) An Assessment of the Expected Cost-Effectiveness of Quadrivalent Influenza Vaccines in Ontario, Canada Using a Static Model. PLOS ONE 10:7, pages e0133606.
Crossref
Crossref